Newsroom

LATEST PUBLICATIONS

From prognostication to precision in acute myeloid leukemia

Invivoscribe Marketing2025-05-08T16:47:49-07:00May 8th, 2025|

Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3 ITD mutated AML

Invivoscribe Marketing2025-05-09T09:20:30-07:00May 8th, 2025|

Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina^® MiSeq^TM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay

wmm2025-03-18T17:44:25-07:00November 8th, 2024|

Performance Comparison of Invivoscribe’s LymphoTrack^® Assays Between Complete Genomics DNBSEQ-G99 and Illumina^® MiSeq^TM NGS Platforms

wmm2025-03-18T17:44:43-07:00November 8th, 2024|

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

Invivoscribe Marketing2024-06-21T12:55:12-07:00June 21st, 2024|

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

Hayden Ogden2025-07-07T22:25:43-07:00July 7th, 2025|

LabPMM Receives New York State Approval for the NPM1 MRD Assay – Informing Therapy and Accelerating Targeted Trials

Invivoscribe Marketing2025-06-17T21:44:30-07:00June 17th, 2025|

Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay

wgarnica2025-04-22T00:41:28-07:00April 22nd, 2025|

Invivoscribe Announces Registration of the LeukoStrat^® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland

Invivoscribe Marketing2025-03-28T10:05:45-07:00March 27th, 2025|

EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA

wmm2024-10-08T03:14:44-07:00October 8th, 2024|

32nd Japanese Society for Gene Diagnosis and Therapy

July 11-12, 2025
Hamamatsu, Japan
Attending

26th JSLH

July 26-27, 2025
Kyoto, Japan
Attending

ADLM

July 27-31, 2025
Chicago, IL
Attending
Visit Conference Website

CGC

August 3-6, 2025
Houston, TX
On-site Booth
Visit Conference Website

SOHO

September 3-6, 2025
Houston, TX
On-site Booth
Visit Conference Website

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Newsroom

Newsroom

LATEST PUBLICATIONS

LATEST PRESS

CONFERENCES

32nd Japanese Society for Gene Diagnosis and Therapy

26th JSLH

ADLM

CGC

SOHO

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.